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Abstract
Background: Concomitant Surgical AF ablation is an established procedure, recommended in guidelines. However
many surgeons are reluctant to perform AF ablation in patients with significantly enlarged left atrium. We therefore
analyzed outcomes of patients with left-atrial diameter >55 mm undergoing concomitant AF ablation.
Methods: Between 05/2003 and 12/2012 124 patients with significantly enlarged left-atrium >55 mm underwent
concomitant surgical AF ablation. Rhythm monitoring was accomplished by implantable loop recorder (ILR)
interrogation (n = 54), or 24-h Holter-ECG (n = 70). Successful ablation was defined as AF Burden <0.5 % in ILR
interrogation or absence of AF episode >30 s in 24-h Holter-ECG. Primary endpoint of the study was freedom from
AF at 12 months follow-up.
Results: Mean patient’s age was 65.7+/−9.6 years, 69.4 % were male. No major ablation or ILR related
complications occurred. Mean LA diameter was 60.7+/−4.4 mm. Survival rate at one-year follow up was
94.4 %. 11 (8.8 %) patients received additional catheter-based ablation, while 23 (18.5 %) had an electrical
cardioversion during follow-up period. Overall freedom from AF rate after one-year follow-up was 64.4 % and
59.4 % off antiarrhythmic drugs respectively. Logistic regression analysis identified preoperative paroxysmal AF,
duration of AF and LA diameter > 70 mm as predictors for rhythm outcome at 12 months follow-up.
Conclusion: In this patient cohort with significantly enlarged LA diameter, concomitant surgical AF ablation
provided freedom from AF of 64.4 % after one-year follow-up. However in this patient population, an
accurate postoperative care with interventions like medical or- electrical cardioversion and additional catheter
based ablation is necessary to achieve satisfactory results.
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Background
Atrial fibrillation (AF), the most common arrhythmia in
patients undergoing cardiac surgery, is associated with
an increased risk of death, stroke, and hospitalisation,
and is furthermore known to reduce quality of life and
exercise capacity [1, 2]. Therefore, the 2012 Guidelines
for the management of AF issued by the European
Society of Cardiology (ESC), European Association of
Cardiothoracic Surgery (EACTS), and European Heart
Rhythm Association (EHRA) recommend concomitant
surgical AF ablation for symptomatic patients, as well
as asymptomatic patients with low risk for an ablation
procedure [3]. Cox first reported his technique of surgical
AF ablation using the cut-and-sew principle in 1987. This
technique was modified and resulted in the so-called Cox
maze III procedure, which, because of its excellent results,
with success rates > 90 %, remained the gold-standard for
surgical AF ablation for many years. However, owing to its
complexity, only a few surgeons performed this procedure.
Within years, the cut-and-sew principle was replaced by
the application of various energy sources to create trans-
mural atrial lesions, and the use of the procedure became
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widespread [4]. In recent studies published success rates
of surgical AF ablation are ranging between 65 % and
90 %, depending on preoperative type of AF, used lesion
set and follow-up method [5–10]. Some studies, investi-
gating predictors for rhythm results after AF ablation,
have shown, that an enlarged left-atrium >55 mm is asso-
ciated with a higher risk of ablation failure [10–13].
Therefore, many surgeons are reluctant to perform con-
comitant surgical ablation procedures in this patient co-
hort. However there is only little relevant information in
the literature, and no clear data exist if there is any certain
LA diameter which is associated with impaired results and
should probably be used as a cut-off value. Therefore, we
aimed to investigate the safety and efficacy of concomitant
surgical AF ablation in patients with a severely enlarged
LA diameter >55 mm.
Methods
Between May 2003 and December 2012, 603 patients
underwent concomitant surgical ablation in our institu-
tion. In 124 of these patients a severely enlarged left
atrium (>55 mm) was observed on preoperative echocar-
diography. 82 (66.1 %) patients were treated due to per-
sistent or longstanding-persistent AF, while 42 (33.9 %)
received ablation for paroxysmal AF. Data of these pa-
tients were prospectively collected into a database and a
retrospectively analyzed.
Isolated bilateral pulmonary vein ablation was per-
formed in 12 (9.7 %) patients. Complete left atrial abla-
tion including pulmonary vein isolation, box lesions, and
left atrial appendage and isthmus isolation was per-
formed in 78 (62.9 %) patients. Biatrial ablation was con-
ducted in 34 (27.4 %) cases, which included additional
right atrial intercaval lesion, isolation of the cavotricus-
pid isthmus, right atrial appendage and terminal crest.
Pulmonary vein isolation was only used in patients
with paroxysmal AF, while biatrial ablation was only
used in patients with persistent AF. Complete left-atrial
lesion set was used in 30 patients with paroxysmal AF
and in 48 patients with persistent- or longstanding per-
sistent AF. Relatively low number of patients receiving
biatrial lesion set is associated to the fact that we first
started to use biatrial ablation in our institution in 2008.
Nowadays, patients with longstanding-persistent AF all
receive a biatrial lesion set.
The energy sources applied included argon-based
cryoablation (cryoICE cryo-ablation probe, AtriCure Inc.,
West Chester, OH, USA; Cardioblate CryoFlex Surgical
Ablation Probe, Medtronic Inc., Minneapolis, MN, USA)
in 24 patients, unipolar radiofrequency ablation (Cardio-
blate unipolar RF pen, Medtronic Inc.) in 51 patients, and
bipolar ablation (Cardioblate BP2 device and Cardioblate
Surgical Ablation System Generator, Medtronic Inc.) in 39
patients.
Statistical analysis
All statistical analyses were performed using SPSS statis-
tical software version 21.0 (SPSS Inc., Chicago, IL, USA).
Continuous values are expressed as mean ± standard devi-
ation and were compared using Student’s t-test or the
Mann–Whitney test, as appropriate. Categorical variables
are displayed as frequencies, and percentages were com-
pared using the chi-square test or Fisher’s exact test, as
appropriate. P < 0.05 was considered statistically signifi-
cant. Reported P values are two-sided. Cox regression ana-
lysis was used to determine survival rates and predictors
for freedom from AF at 1-year follow-up. ROC analysis
was used to identify a cut-off value for LA diameter.
Follow-up
All rhythm results were obtained by either implantable
loop recorder (ILR) interrogation (n = 54), or 24-h Hol-
ter-ECG (n = 70) at three and 12 months’ follow-up.
AF recurrence was defined as an AF burden > 0.5 % in
ER interrogation or a single AF episode with dur-
ation > 30 s on the 24-h Holter ECG. Postoperative as
well as discharge rhythm results were obtained using
12-lead ECG. The antiarrhythmic drugs and anticoagu-
lation regimens were maintained for 3 months postop-
eratively in all patients and then adapted according to
the rhythm results. In patients without contraindica-
tions, amiodarone was used as first-line antiarrhythmic
drug therapy; otherwise, other class I or III antiar-
rhythmic drugs were used for at least three months
postoperatively. Echocardiography was performed
prior to the surgical procedure.
Results
Demographic and intraoperative data
Baseline patient characteristics are displayed in Table 1.
Mean patients’ age was 68.7 ± 9.7 years. Mean left atrial
diameter was 60.7+/−4.4 mm. Mean AF duration was
4.1 ± 3.8 years. Mean preoperative LVEF was 51.0 % ±
11.7 %. 8 (6.4 %) patients had a history of stroke. Per-
formed surgical procedures were isolated coronary artery
bypass grafting (CABG) in 24 patients, aortic valve re-
placement in 20 patients, and mitral valve repair or re-
placement in 22 patients. A combined CABG and valve
operation was performed in 43 patients; other surgical
procedures made up the remaining 15 cases. No major
ablation-related complications occurred in any of the pa-
tients. 2 patients (1.6 %) experienced perioperative stroke,
while 3 patients experienced stroke during 12 months
follow-up period. Postoperative new permanent pace-
maker implantation rate was 10.1 %.
Rhythm results
Freedom from AF was recorded by 12-lead ECG imme-
diately after the procedure and at the time of discharge
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in 52 % and 46 % of patients, respectively. All patients
underwent either ER interrogation (n = 54) or 24-h Hol-
ter ECG monitoring (n = 70) at three and 12 months’
follow-up. 67 patients (54.0 %) also attended a six-
month follow-up. At three and six months’ follow-up,
51 % and 55 % of patients, showed freedom from AF. At
12 months’ follow-up, freedom from AF was 64.4 %, and
59.4 % off anti-arrhythmic drugs respectively (Fig. 1). Pa-
tients with preoperative paroxysmal AF had statistically
significant higher rate of freedom from AF, compared to
patients with persistent AF, (74.2 % vs. 55.3 %; p = 0.02).
Cox regression analysis was used to identify predictors
for freedom from AF after 12 months. Preoperative
paroxysmal AF (p = 0.017 OR: 1.36 CI: 1.08-2.31) as
well as shorter duration of AF (p = 0.03 OR 1.14 CI:
0.98-1.70) were statistically significant predictors for
freedom from AF after 12 months. Furthermore an
LA diameter >70 mm was identified in ROC analysis
to be a cut off value, predicting ablation failure. Nei-
ther demographic data, indication for surgery, lesion
set and used energy source had an impact on SR rate
after one year.
Additional procedures
In patients with persistent AF at the time of follow up,
electrical cardioversion was initiated. Patients with re-
currence of AF 6 months postoperatively were consid-
ered for additional catheter-based ablation, if reasonable.
During follow-up period, 23 (18.5 %) received electrical
cardioversion, while 11 (8.8 %) had an additional
catheter based-ablation. In patients receiving catheter
ablation, electrophysiological mapping was performed.
5 patients had gaps in the surgically performed lines,
while in 6 patients additional lines were performed. 3
of them were treated due to atrial flutter.
Survival
There were no cases of intraoperative death. The in-
hospital mortality rate was 1.8 %, while the 30-day mor-
tality rate was 2.7 %. The one-year survival rate was
94 % for the entire patient population. There were no
differences in survival between patients with successful
ablation and those with ablation failure during 1-year
follow-up period.
Table 1 Patients’ characteristics
Patients n = 124
Age (years) 68.7 ± 9.7
Gender (female/male) 38/86
AF duration (years) 4.1 ± 3.8
Paroxysmal AF n (%) 42 (33.9)
LA diameter (mm) 60.7 ± 4.4
LVEF (%) 51.0 ± 11.7
Prior Stroke n (%) 8 (6.4)
Diabetes n (%) 25 (20.2)
Renal insuffiency n (%) 15 (12.1)
COPD n (%) 10 (8.1)
Coronary artery disease n (%) 45 (36.3)
Previous MI n (%) 18 (14.5)
Fig. 1 Rhythm results during follow-up
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Discussion
This study investigates the impact of concomitant surgi-
cal AF ablation in a patient cohort with significantly en-
larged LA > 55 mm. We have shown, that even in this
group of patients, that is considered as a population with
high risk for ablation failure by many surgeons, satisfac-
tory results for SR restoration can be achieved. Freedom
from AF was 64.4 % and 59.4 % off antiarrhythmic drugs
after one-year follow up in our study. We observed sig-
nificantly higher SR restoration rate results in patients
with preoperative paroxysmal AF, compared to those
with persistent- or long-standing persistent AF, a finding
which is well-known and in line with several previously
published papers. Searching for predictors of ablation
success, in our study, preoperative paroxysmal AF was
the only statistically significant predictor in univariate
logistic regression analysis. In contrast to other previ-
ously published studies, we did not observe an influence
of the used lesion set on ablation success [14, 15]. Espe-
cially in patients with persistent- or longstanding persist-
ent AF several studies have shown superior results for
biatrial ablation [9, 15]. However our results may be ex-
plained due to the relatively small number of patients
that received biatrial lesion set in our cohort, so that the
statistical power might be too small and superior results
in the biatrial group might not reach statistical signifi-
cance. Furthermore we did not find any influence of the
used energy source on ablation success, a result that has
been also published by other groups.
Also the type of surgical procedure did not influence
the rhythm outcome in patients with significantly en-
larged LA. We found that patients with larger LA had
more often Mitral valve disease, an observation, previ-
ously described in other studies [16].
Several studies have shown an impact of LA size on
ablation success. Damiano et al. have reported that an
enlarged LA diameter is a predictor for late failure after
Cox-Maze IV procedure [11]. Similar observation has
been previously published by our group in a cohort of
503 patients receiving surgical AF ablation. In a multi-
variate logistic regression analysis we also found LA size
to be a predictor for ablation failure [10]. Ad et al. have
published a study of patients with surgical AF ablation,
where they compared outcomes of patients with LA diam-
eter > 55 mm with those with LA diameter <55 mm. In
the one-year analysis patients with small LA had superior
results, but at 2 year follow-up patients with large and
small atria had similar SR rates.
In our study we found that patients with enlarged LA
>55 mm still have good SR rate after 1-year follow-up.
However in logistic regression analysis, LA diameter of
70 mm seems to be a cut-off value where ablation re-
sults tend to be significantly worse. This finding is in
line with the data published by Ad et al., they observed
an LA diameter between 70 and 80 mm as predictor for
failure of ablation [16].
In our patient population, surgical AF ablation was
safe and feasible in this group of patients with signifi-
cantly enlarged LA. We had no ablation-related mor-
tality or morbidity in any of our patients. These
findings are consistent with a previously published
study of Ad et al. They showed, in a propensity-score
matched analysis of 178 high-risk patients with an
additive Euroscore > 6, that even in a high risk cohort,
there is no additional operative risk when performing
AF ablation compared to a non-ablation group [17].
The one-year survival rate was 94.4 % in our cohort
without differences in patients with SR restoration and
those with failure of ablation. There is only little pub-
lished data on the effect of SR restoration after AF abla-
tion on survival. According to our data, survival rates
did not differ significantly between patients with- or
without successful AF ablation. This finding is in con-
trast with a previous published study by Louagie et al.,
in which a successful Cox maze procedure with restor-
ation of sinus rhythm resulted in a higher survival rate
in those patients [18]. Furthermore previous published
study by McCarthy et al. has shown a mid-term survival
benefit for patients with AF receiving concomitant surgi-
cal ablation. In their propensity-score matched analysis
including 4947 patients, they compared patients with AF
receiving ablation (n = 423), patients with AF receiving
no ablation (n = 129) and patients without AF. They
found out that patients in the AF ablation group had
lower mortality during mid- term follow-up, compared
with patients with AF without ablation. The mortality
rate of treated patients at last follow-up was similar to
those of patients without AF [19].
The absence of a demonstrable survival benefit for pa-
tients who had sinus rhythm restoration in our study
could be due to the relatively small number of patients
and the limited follow-up time of 12 months.
In our patient population, 64.4 % of patients were in
sinus rhythm after a one-year follow-up. All rhythm re-
sults were obtained using 24-h Holter ECG or ER moni-
toring, according to the 2012 published ESC/EHRA/
EACTS guidelines [3]. This may be one of the reasons
for the lower sinus rhythm rates compared to previous
published studies where the rhythm follow-up used only
12-lead ECG [12, 20]. Another reason may be the fact
that we were dealing with a population with a signifi-
cantly enlarged AF > 55 mm where the success rates
of AF ablation tend to be lower. However, given the
potential long-term benefits of the restoration of
sinus rhythm, particularly in patients concomitant
surgical ablation is worth considering even in this
surgically high-risk population, despite of potentially
longer operative times.
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Major limitation of the study is the retrospective single
centre study design with the potential risk of bias by un-
known confounders. Especially the inhomogeneous pa-
tient collective in our study makes it difficult to draw
conclusions regarding lesion sets or energy sources in pa-
tients with significantly enlarged LA diameter. Further-
more our patient population consisted of a relatively small
number of patients, and larger prospective randomized
trials with more homogeneous patient population will be
necessary to confirm the obtained results.
Conclusion
In this patient cohort with significantly enlarged LA
diameter, concomitant surgical AF ablation provided still
a rate of freedom from AF of 64.4 % after one-year
follow-up. Univariate logistic regression analysis identi-
fied LA duration, preoperative paroxysmal AF and LA
diameter >70 mm as statistically significant predictors
for rhythm outcome. However in this patient population,
an accurate postoperative care with interventions like
medical or- electrical cardioversion and additional cath-
eter based ablation is necessary to achieve satisfactory
results.
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